Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Profit Outlook

By
Simply Wall St
Published
February 17, 2022
NasdaqGM:ARCT
Source: Shutterstock

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. With the latest financial year loss of US$72m and a trailing-twelve-month loss of US$196m, the US$645m market-cap company amplified its loss by moving further away from its breakeven target. Many investors are wondering about the rate at which Arcturus Therapeutics Holdings will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Check out our latest analysis for Arcturus Therapeutics Holdings

According to the 10 industry analysts covering Arcturus Therapeutics Holdings, the consensus is that breakeven is near. They expect the company to post a final loss in 2022, before turning a profit of US$196m in 2023. So, the company is predicted to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2023? Working backwards from analyst estimates, it turns out that they expect the company to grow 52% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth
NasdaqGM:ARCT Earnings Per Share Growth February 17th 2022

We're not going to go through company-specific developments for Arcturus Therapeutics Holdings given that this is a high-level summary, however, bear in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital prudently, with debt making up 23% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Arcturus Therapeutics Holdings, so if you are interested in understanding the company at a deeper level, take a look at Arcturus Therapeutics Holdings' company page on Simply Wall St. We've also put together a list of relevant factors you should further examine:

  1. Historical Track Record: What has Arcturus Therapeutics Holdings' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Arcturus Therapeutics Holdings' board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.